Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q43050781)
Watch
English
Fibrates in CVD: a step towards personalised medicine
scientific article published in May 2010
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
title
Fibrates in CVD: a step towards personalised medicine
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
author
Bart Staels
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
language of work or name
English
0 references
publication date
1 May 2010
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
volume
375
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
issue
9729
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
page(s)
1847-1848
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
cites work
Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fibrates, glitazones, and peroxisome proliferator-activated receptors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of combination lipid therapy in type 2 diabetes mellitus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety considerations with fibrate therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(10)60758-1
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
PubMed ID
20510999
1 reference
stated in
Europe PubMed Central
PubMed ID
20510999
retrieved
13 November 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit